An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral Density Previously Treated With Alendronate
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2013
At a glance
- Drugs Romosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- Sponsors Amgen
- 17 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 17 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 May 2012 New trial record